Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influencing Progression of Airway Disease in Primary Antibody Deficiency (IPAD Trial)
2024-513124-41-00Phase 3Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of polyvalent human immunoglobulin, ALYGLO, Human normal immunoglobulin G, Nanogam, kiovig and 1 more in Primary antibody deficiency (PAD), Unclassified Antibody Deficiency (UAD), Immunoglobulin A deficiency (IgAD) and 4 more (2 arms), sponsored by University Medical Center Utrecht. Started Jul 2024; status: completed.
02
Drugs
polyvalent human immunoglobulinALYGLOHuman normal immunoglobulin GNanogamkiovig
03
Conditions
Primary antibody deficiency (PAD)Unclassified Antibody Deficiency (UAD)Immunoglobulin A deficiency (IgAD)selective antibody deficiency (SAD)IgG subclass deficiency (IgGSD)
Beyond the preview
Go deeper on 2024-513124-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513124-41-00.